search
Back to results

Impact of Pharmacy Clinic on Diabetes Management (PharmaMD)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pharmacy Managed Diabetes Clinic (PMDC)
Standard of Care (SOC)
Sponsored by
William Beaumont Hospitals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes, pharmacy clinic, education, diabetes complications, hemoglobin A1c, health-care cost, 'no show' rate, compliance, diabetes core measures

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • high risk diabetes mellitus type 2 patients (hemoglobin ≥ 9%)
  • not currently enrolled in PMDC.
  • established with a primary care resident internal medicine or medicine-pediatrics resident.
  • have a diagnosis of diabetes mellitus type 2.

Exclusion Criteria:

  • Patients will be excluded if they have been seen by the PMDC within the past 3 months.
  • under 18 years of age or over 75 years of age.
  • documented as having type 1 diabetes or
  • latent autoimmune diabetes of adults.

Sites / Locations

  • Beaumont Geriatric Assessment Center
  • Beaumont Outpatient Clinic
  • Beaumont Internal Medicine Center
  • Norton, Klein, Hug, Sabin and Maddens Internal Medicine & Primary Care Practice

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard of Care (SOC)

SOC and PMDC

Arm Description

The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP

The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.

Outcomes

Primary Outcome Measures

Hemoglobin A1c at 6 Months
change from baseline in Hemoglobin A1c, measured in % DCCT (Diabetes Control and Complications Trial) units
Hemoglobin A1c at 12 Months
change from baseline in Hemoglobin A1c

Secondary Outcome Measures

Hemoglobin A1c Less Than 8% at 6 Months
Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0%
Hemoglobin A1c Less Than 8% at 12 Months
Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0% DCCT units
Change in Hemoglobin A1c From 6 to 12 Months
The change in hemoglobin A1c (HbA1c), between 6 months and 12 months after randomization.
Achievement of Annual Lipid Panel Testing
percentage of patients complying with annual lipid testing
Statin Compliance
Percentage of patients compliant with statin therapy per the 2013 American College of Cardiology / American Heart Association guidelines.
Blood Pressure
Percentage of patients achieving Blood pressure goal of less than 140/90 at the end of the trial period.
Annual Retinopathy Examination
Percentage of patients compliant with annual retinopathy examination
Annual Nephropathy Examination
Percentage of patients compliant with annual nephropathy examination
Annual Neuropathy Examination
Percentage of patients compliant with annual neuropathy examination
Annual Influenza Vaccine
Percentage of patients compliant with annual influenza vaccine
Annual Pneumonia Vaccine
Percentage of patients compliant with annual pneumonia vaccine
Quality of Life Assessment
Difference between quality of life assessment via the World Health Organization BREF-Quality Of Life at baseline and 12 months.The WHOQOL-BREF consists of 4 domains, Physical Health, Psychological, Social Relationships, and Environment. Each domain is comprised of multiple questions that are considered together in the derivation of each domain score. In addition to the 4 domains, the WHOQOL-BREF includes two stand-alone questions to assess rated QOL and Satisfaction with Health questionnaire administered at baseline and at the conclusion of the trial period. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life) and range from a minimum of 4 to a maximum of 20. The mean score of items within each domain is used to calculate the domain score.A Likert scale from 1-7 was used. (1 - not affected, 7- extremely affected) We compared and reported the mean difference in between 6 months data and baseline data.
Diabetes Related EC Visits at 6 Months
Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia
Diabetes Related EC Visits at 12 Months
Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia
Total EC Visits at 6 Months
Number of Emergency Center (EC) visits
Total EC Visits at 12 Months
Number of Emergency Center (EC) visits
Inpatient Visits
Total number of inpatient visits
Outpatient Visits
total number of outpatient visits
No-show
percentage of visits missed in clinic

Full Information

First Posted
December 13, 2017
Last Updated
June 29, 2021
Sponsor
William Beaumont Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT03377127
Brief Title
Impact of Pharmacy Clinic on Diabetes Management
Acronym
PharmaMD
Official Title
PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
February 19, 2018 (Actual)
Primary Completion Date
May 22, 2020 (Actual)
Study Completion Date
November 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
William Beaumont Hospitals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The Beaumont Hospital Royal Oak Outpatient Clinic (and other listed Beaumont recruiting locations) care for over 900 patients with diabetes. In an effort to improve the care provided to our patients, a pharmacist managed diabetes clinic (PMDC) was created. The investigators looked at patients with high-risk diabetes who have received education in the PMDC and compared them to patients that didn't not receive the pharmacy education. Our preliminary data showed a significant decrease in Hemoglobin A1c in the PMDC compared to our standard care cohort. Hemoglobin A1c is a marker of the severity of diabetes mellitus. Based on this data, we designed a randomized controlled trial to better assess the impact of a PMDC on diabetic outcomes.
Detailed Description
Over the past 20 years, the number of adults with diabetes has tripled in the United States. According to the Centers for Disease Control (CDC), diabetes mellitus (DM) affected 30.2 million American adults in 2015. Previous studies showed that for each 1% reduction in hemoglobin A1c (HbA1c), there was a corresponding 14% reduction in myocardial infarction, 12% reduction in stroke, and a 37% reduction of microvascular complications. Based on our preliminary data, a Pharmacist Managed Diabetes Clinic (PMDC) had a decrease in HbA1c of 2.2% in the high-risk diabetes patients from the PMDC cohort versus 0.9% in the standard care cohort (p=0.006). At six months there was a decrease in HbA1c of 3.2% in the PMDC and 1.2% in the standard care cohort (p=0.044). Our hypothesis is that a pharmacist managed diabetes clinic focused on patient identified diabetes management gaps and goals would have a significant positive impact on diabetes core measures and will result in a higher quality of care at a lower price. A randomized controlled trial (RCT) of our PMDC would provide further clarity on the impact on patient outcomes and important evidence with regard to how the physicians can deliver the best care for this high-risk population. Trial design This is a randomized open-label, controlled parallel group trial of a pharmacist managed diabetes clinic in high-risk diabetes patients, with a 1:1 allocation to either standard of care (SOC) or SOC and PMDC and a 6-month and 12-month follow-up. Methods: The study will be conducted at the listed recruiting sites at Beaumont Hospital. Michigan. The outpatient clinic is a resident clinic that delivers medical care to over 920 patients with diabetes mellitus. The clinic is based on campus at Beaumont Hospital, Royal Oak. Potential subjects with high-risk diabetes mellitus will be identified through weekly reports and from the daily schedule and will be recruited from this pool of patients exclusively. Intervention The patients will be enrolled over a 6-month period and will be randomly assigned to control group (usual care) and the intervention group (usual care plus PMDC visits). The PMDC is a pharmacist-led clinic that has been functioning in our outpatient clinic since January 2015 and is considered an available resource. The intervention group patients will be managed by their assigned primary care physicians (PCPs), per standard of care and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The PMDC visits will be scheduled more frequent in the first 2 months of the intervention to ensure patients' engagement and provide enough opportunities and time to address all the patients' goals and concerns. The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes. Patients will be asked to describe their own gaps in knowledge and to identify their own management goals. Identification of knowledge gaps will allow targeted patient education to close those gaps. Other educational opportunities will potentially include diabetes mellitus pathophysiology, blood glucose goals, HbA1c goals, management of hyperglycemic and hypoglycemic episodes, review of medications, and counseling regarding diet and exercise. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician. The control group patients will be managed by their assigned PCPs, per standard of care. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP. Outside the intervention, the participants in both groups will be treated identical. They will participate in the standard of care visits at baseline, at 3 months and at 6 months. These visits (visit 1, 6 and 9 in the intervention group and visit 1, 2 and 3 in the standard of care group) will be provided by each patient's primary care physician

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes, pharmacy clinic, education, diabetes complications, hemoglobin A1c, health-care cost, 'no show' rate, compliance, diabetes core measures

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a randomized open-label, controlled parallel group trial of a pharmacist managed diabetes clinic in high-risk diabetes patients, with a 1:1 allocation to either standard of care (SOC) or SOC and PMDC and a 6-month and 12-month follow-up.
Masking
InvestigatorOutcomes Assessor
Masking Description
The patients and physicians will not be blinded to the intervention. However, the data collectors and the data analysts will be unaware of the patients allocation. The outcome assessors will also not be aware of the allocation. The biostatistician will also be blinded.
Allocation
Randomized
Enrollment
86 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of Care (SOC)
Arm Type
Active Comparator
Arm Description
The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
Arm Title
SOC and PMDC
Arm Type
Experimental
Arm Description
The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
Intervention Type
Behavioral
Intervention Name(s)
Pharmacy Managed Diabetes Clinic (PMDC)
Intervention Description
The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
Intervention Type
Other
Intervention Name(s)
Standard of Care (SOC)
Intervention Description
Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
Primary Outcome Measure Information:
Title
Hemoglobin A1c at 6 Months
Description
change from baseline in Hemoglobin A1c, measured in % DCCT (Diabetes Control and Complications Trial) units
Time Frame
6 months
Title
Hemoglobin A1c at 12 Months
Description
change from baseline in Hemoglobin A1c
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Hemoglobin A1c Less Than 8% at 6 Months
Description
Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0%
Time Frame
6 months
Title
Hemoglobin A1c Less Than 8% at 12 Months
Description
Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0% DCCT units
Time Frame
12 months
Title
Change in Hemoglobin A1c From 6 to 12 Months
Description
The change in hemoglobin A1c (HbA1c), between 6 months and 12 months after randomization.
Time Frame
12 months
Title
Achievement of Annual Lipid Panel Testing
Description
percentage of patients complying with annual lipid testing
Time Frame
12 months
Title
Statin Compliance
Description
Percentage of patients compliant with statin therapy per the 2013 American College of Cardiology / American Heart Association guidelines.
Time Frame
12 months
Title
Blood Pressure
Description
Percentage of patients achieving Blood pressure goal of less than 140/90 at the end of the trial period.
Time Frame
12 months
Title
Annual Retinopathy Examination
Description
Percentage of patients compliant with annual retinopathy examination
Time Frame
12 months
Title
Annual Nephropathy Examination
Description
Percentage of patients compliant with annual nephropathy examination
Time Frame
12 months
Title
Annual Neuropathy Examination
Description
Percentage of patients compliant with annual neuropathy examination
Time Frame
12 months
Title
Annual Influenza Vaccine
Description
Percentage of patients compliant with annual influenza vaccine
Time Frame
12 months
Title
Annual Pneumonia Vaccine
Description
Percentage of patients compliant with annual pneumonia vaccine
Time Frame
12 months
Title
Quality of Life Assessment
Description
Difference between quality of life assessment via the World Health Organization BREF-Quality Of Life at baseline and 12 months.The WHOQOL-BREF consists of 4 domains, Physical Health, Psychological, Social Relationships, and Environment. Each domain is comprised of multiple questions that are considered together in the derivation of each domain score. In addition to the 4 domains, the WHOQOL-BREF includes two stand-alone questions to assess rated QOL and Satisfaction with Health questionnaire administered at baseline and at the conclusion of the trial period. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life) and range from a minimum of 4 to a maximum of 20. The mean score of items within each domain is used to calculate the domain score.A Likert scale from 1-7 was used. (1 - not affected, 7- extremely affected) We compared and reported the mean difference in between 6 months data and baseline data.
Time Frame
12 months
Title
Diabetes Related EC Visits at 6 Months
Description
Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia
Time Frame
6 months
Title
Diabetes Related EC Visits at 12 Months
Description
Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia
Time Frame
12 months
Title
Total EC Visits at 6 Months
Description
Number of Emergency Center (EC) visits
Time Frame
6 months
Title
Total EC Visits at 12 Months
Description
Number of Emergency Center (EC) visits
Time Frame
12 months
Title
Inpatient Visits
Description
Total number of inpatient visits
Time Frame
12 months
Title
Outpatient Visits
Description
total number of outpatient visits
Time Frame
12 months
Title
No-show
Description
percentage of visits missed in clinic
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: high risk diabetes mellitus type 2 patients (hemoglobin ≥ 9%) not currently enrolled in PMDC. established with a primary care resident internal medicine or medicine-pediatrics resident. have a diagnosis of diabetes mellitus type 2. Exclusion Criteria: Patients will be excluded if they have been seen by the PMDC within the past 3 months. under 18 years of age or over 75 years of age. documented as having type 1 diabetes or latent autoimmune diabetes of adults.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra I Halalau, MD
Organizational Affiliation
Director of Internal Medicine Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beaumont Geriatric Assessment Center
City
Berkley
State/Province
Michigan
ZIP/Postal Code
48072
Country
United States
Facility Name
Beaumont Outpatient Clinic
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Beaumont Internal Medicine Center
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48034
Country
United States
Facility Name
Norton, Klein, Hug, Sabin and Maddens Internal Medicine & Primary Care Practice
City
Troy
State/Province
Michigan
ZIP/Postal Code
48084
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35296307
Citation
Halalau A, Sonmez M, Uddin A, Karabon P, Scherzer Z, Keeney S. Efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients, a randomized controlled trial - "Pharm-MD" : Impact of clinical pharmacists in diabetes care. BMC Endocr Disord. 2022 Mar 16;22(1):69. doi: 10.1186/s12902-022-00983-y.
Results Reference
derived
PubMed Identifier
30143033
Citation
Halalau A, Shelden D, Keeney S, Hehar J. Pharm-MD; an open-label, randomized controlled, phase II study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients - study protocol for a randomized controlled trial. Trials. 2018 Aug 24;19(1):458. doi: 10.1186/s13063-018-2836-8.
Results Reference
derived

Learn more about this trial

Impact of Pharmacy Clinic on Diabetes Management

We'll reach out to this number within 24 hrs